CPC Introduces Innovative Aseptic Micro-Connector for Cell and Gene Therapy Freeze Cassettes

CPC (Colder Products Company), part of Dover  and a leading manufacturer of connection technologies used in biopharmaceutical processing, today...

September 12, 2024 | Thursday | News
Symbiosis Pharmaceutical Expands Manufacturing Capacity with New Facility in Stirling

Symbiosis Pharmaceutical Services Ltd (Symbiosis), a rapidly growing sterile biopharmaceutical Contract Manufacturing Organisation (CMO) announces the pu...

September 09, 2024 | Monday | News
Scantox Group Acquires UK-Based Gentronix to Expand Genetic Toxicology Services

Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Resear...

September 09, 2024 | Monday | News
Valneva and Pfizer Report Positive Phase 2 Results for Lyme Disease Vaccine Candidate, VLA15, Following Second Booster Dose

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) today announced positive results from the VLA15-221 Phase 2 study of t...

September 03, 2024 | Tuesday | News
Sanofi’s Tolebrutinib Shows First Disability Reduction in Phase 3 nrSPMS Study

Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary...

September 02, 2024 | Monday | News
HUTCHMED Voluntarily Withdraws Supplemental NDA for Fruquintinib in China, Cites Need for Further Evaluation in Gastric Cancer Treatment

HUTCHMED announces that it has voluntarily withdrawn its supplemental New Drug Application (“NDA”) in China for fruquintinib in combination w...

August 30, 2024 | Friday | News
Celltrion USA Expands Patient Access to ZYMFENTRA® Through Agreement with Cigna and Express Scripts

Celltrion USA announced that it has signed an agreement with Cigna Healthcare, the health benefits provider of the Cigna Group and Express Scripts, the p...

August 29, 2024 | Thursday | News
AC Immune's Partner LMI Receives FDA Fast Track Designation for PI-2620 in Alzheimer's and Other Neurodegenerative Diseases

  PI-2620 is in Phase 3 development in Alzheimer’s disease by AC Immune’s partner, LMI This Fast Track designation applies across Al...

August 28, 2024 | Wednesday | News
LIXTE Biotechnology and Netherlands Cancer Institute Dose First Patient in Roche-Supported Trial for Metastatic Colorectal Cancer

LIXTE Biotechnology Holdings, Inc. announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer In...

August 27, 2024 | Tuesday | News
Curebound Announces Major Milestones for Cancer Research Grants, Secures Over $5.3M in Follow-On Funding

-Curebound, a philanthropic organization that raises and invests strategic funding for cancer research, is announcing important updates on its grant reci...

August 22, 2024 | Thursday | News
Pfizer and BioNTech's Ambitious Combo Vaccine Shows Promise but Faces Hurdles in Phase 3 Trial

In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicit...

August 19, 2024 | Monday | News
Incyte Announces Positive Phase 3 Trial Results for Tafasitamab in Relapsed or Refractory Follicular Lymphoma

Incyte  announces positive topline results from the pivotal Phase 3 inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®), a...

August 16, 2024 | Friday | News
Gilead Sciences Announces FDA Accelerated Approval for Livdelzi® in Treating Primary Biliary Cholangitis

Gilead Sciences, Inc.  announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi® (seladelpar) fo...

August 15, 2024 | Thursday | News
Renexxion and Dr. Falk Pharma Begin U.S. Patient Dosing in Global Phase 2b Study for Promising Gastroparesis Treatment

Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to patients with high u...

August 14, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close